AbbVie Submits BLA for Etentamig, a Novel BCMA Bispecific for Multiple Myeloma

What happened

AbbVie announced submission of a Biologics License Application to the FDA for etentamig, a second-generation BCMA x CD3 bispecific antibody for relapsed/refractory multiple myeloma, with Phase 3 CERVINO data showing improved ORR and PFS versus standard of care. The submission aligns with AbbVie's stated ambition to build a broad multiple myeloma portfolio and adds a potential oncology growth avenue beyond the company's core immunology and aesthetics franchises. The master report's focus remains on Skyrizi and Rinvoq, which carry ~42% of 2025 revenue, and on aesthetics stabilization, with no prior mention of etentamig in the near-term catalysts. Etentamig's intravenous administration and clinical profile could support use in community settings, but it enters a competitive BCMA bispecific field already populated by approved agents from J&J and Pfizer. While the BLA is a regulatory milestone, it does not yet affect the 2026 revenue and free cash flow algorithm, and its commercial impact is uncertain pending FDA review and market dynamics.

Implication

If etentamig gains approval and demonstrates competitive advantages such as better safety or dosing convenience, it could diversify revenue away from the two-product concentration in immunology, potentially supporting a higher multiple over time; however, the oncology market is crowded, and AbbVie will need to show meaningful uptake to alter the thesis. The master report's attractive entry of $210 remains relevant, and any positive etentamig data could reduce downside risk but not justify chasing the stock above $245 without confirmation in core franchises.

Thesis delta

The etentamig BLA does not change the core thesis, which remains contingent on Skyrizi and Rinvoq delivering the 2026 immunology framework and on aesthetics tracking to the $5.0B guide. However, it modestly increases confidence in AbbVie's pipeline execution and long-term diversification potential, which could become more material if the drug is approved and commercialized successfully. The WAIT rating and valuation parameters remain unchanged.